Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 5, 2005, Pages 378-385

  Wang, Deng Shun ^a   Lipton, Richard B ^b   Katz, Mindy J ^b   Davies, Peter ^b   Buschke, Herman ^b   Kuslansky, Gail ^b   Verghese, Joe ^b   Younkin, Steven G ^a   Eckman, Chris ^a   Dickson, Dennis W ^a  

^a MAYO CLINIC   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Amyloid; Neprilysin; Neurofibrillary tangles; Pathological aging; Senile plaques; Synaptic markers; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; SYNAPTOPHYSIN; TAU PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CADAVER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; HUMAN; IMMUNOREACTIVITY; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; SENILE PLAQUE; WESTERN BLOTTING;

EID: 20944435413     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/64.5.378     Document Type: Article

References (46)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics Science 2002;297:353-56
2. Delaere P, He Y, Fayet G, Duyckaerts C, Hauw JJ. Beta A4 deposits are constant in the brain of the oldest old: An immunocytochemical study of 20 French centenarians. Neurobiol Aging 1993;14:191-94
3. Troncoso JC, Martin LJ, Dal Forno D, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996;17:365-71
4. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathologic aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992;13:179-89
5. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;815:328-37
6. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P Correlations of synaptic and pathologic markers with cognition of the elderly. Neurobiol Aging 1995;16:285-98
7. Dickson DW, Ivanushkin A, Heitner J, Yen S-H, Davies P. Apolipoprotein-E immunoreactivity is increased in deposits of Alzheimer's disease, but not pathologic aging or diffuse Lewy body disease. In: Iqbal H, Mortimer JA, Winblad B, Wisniewski HM, eds. Research Advances in Alzheimer's Disease and Related Disorders. New York: John Wiley & Sons, 1995:371-83
8. Dickson DW, Sinicropi S, Yen S-H, et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 1996;17:733-43
9. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-39
10. Gowing E, Roher AE, Woods AS, et al. Chemical characterization of Abeta 17-42 peptide: A component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 1994;269:10987-90
11. Lalowski M, Golabek A, Lemere CA, et al. The 'nonamyloidogenic' p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 1996;271:33623-31
12. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: Uncovering the secrets of secretases. Curr Opin Neurobiol 2001;11:585-90
13. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002;59:1381-89
14. Yang L, Lindholm BK, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003;9:3-4
15. Tucker HM, Kihiko M, Caldwell JN, et al. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 2000;20:3937-46
16. Sudoh S, Frosch MR Wolf BA. Differential effects of proteases involved in intracellular degradation of amyloid-β-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochem 2002;41:1091-99
17. Miller BC, Eckman EA, Sambamurti K, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003;100:6221-26
18. Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 2001;276:24540-48
19. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003;278:2081-84
20. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathologic deposition. Nat Med 2000;6:143-50
21. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL and PEX. FASEB J 1997;11:355-64
22. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 2001;23:261-69
23. Carson JA, Turner AJ. Beta-amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 2002;81:1-8
24. Fukami S, Watanabe K, Iwata N, et al. Abeta-degrading endopeptidase neprilysin in mouse brain: Synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res 2002;43:39-56
25. Barnes K, Doherty S, Turner AJ. Endopeptidase-2411 is the integral membrane peptidase initiating degradation of somatostatin in the hippocampus. J Neurochem 1995;64:1826-32
26. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of Abeta-degrading endopeptidase neprilysin in mouse hippocampus upon aging. J Neurosci Res 2002;70:493-500
27. Apelt J, Ach K, Schliebs R. Aging-related downregulation of neprilysin: A putative beta-amyloid-degrading enzyme in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett 2003;339:183-86
28. Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res 2001;919:115-21
29. Wang DS, Cochran E, Bennett DM, Eckman EC, Dickson DW, Amyloid, PHF-tau, ubiquitin and synaptic markers in the progression of Alzheimer's disease: Immunochemical analysis of frontal cortex from prospectively studied elderly humans. In: Iqbal K, Sisodia SS, Winblad B, eds. Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. New York: John Wiley & Sons, Ltd, 2001:165-80
30. Image J. Bethesda, MD: Research Services Branch, National Institute of Mental Health. November 17, 2004. Available at: http://rsb.info.nih.gov/ij/
31. Johnson GD, Ahn K. Development of an internally quenched fluorescent substrate selective for endothelin-converting enzyme-1. Anal Biochem 2000;286:112-18
32. Wang DS, Bennett DA, Mufson E, Cochran E, Dickson DW. Decreases in soluble α-synuclein in frontal cortex correlate with cognitive decline in the elderly. Neurosci Lett 2004;359:104-8
33. Fahnoe DC, Knapp J, Johnson GD, Ahn K. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH. J Cardiovasc Pharmacol 2000;36(suppl 1):S22-25
34. Lipton AM, Cullum CM, Satumtira S, et al. Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. Arch Neurol 2001;58:1233-39
35. Takaki Y, Iwata N, Tsubuki S, et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J Biochem (Tokyo) 2000;128:897-902
36. Roher AE, Lowenson JD, Clarke S, et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268: 3072-83
37. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). J Biol Chem 1995;270:7013-16
38. Buschke H, Sliwinski M, Kuslansky G, Lipton RB. Aging, encoding specificity, and memory change in the Double Memory Test. J Int Neuropsychol Soc 1995;1:483-93
39. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. 'Preclinical' AD revisited: Neuropathology of cognitively normal older adults. Neurology 2000;55:370-76
40. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95
41. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998;95:6448-53
42. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-89
43. Wang DS, Iwata N, Hama E, Saido TC, Dickson DW. Oxidized neprilysin in aging and Alzheimer's disease brains. Biochem Biophys Res Commun 2003;310:236-41
44. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset alzheimer's disease pedigrees. Science 2000;290:2303-4
45. Bertram L, Blacker D, Mullin K, et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000;290:2302-3
46. Eckman EA, Eckman CB. Aβ degradation by endothelin-converting enzymes. In: Saido TC, ed. Aβ Metabolism and Alzheimer's Disease. Georgetown, TX: Landes Bioscience, 2003:81-94